A policy analysis in Diabetes Care, written from India, sets out what happened to the cost of modern diabetes therapy here and why. Price reductions of roughly 60-90% for SGLT2 inhibitors and GLP-1 receptor agonists followed patent expiry, driven by generic competition, structured price regulation and government support. Insulin glargine biosimilars are similarly cheaper. Cross-national comparisons put Indian generic prices 15- to 65-fold below US list prices for selected agents.
This matters in clinic because affordability is the commonest unspoken reason a guideline-indicated drug is never started. A clinician working from a price they last checked three or four years ago is making an access judgement on stale data, and is quietly rationing on the patient's behalf. The authors also credit Ayushman Bharat with widening access for poorer patients.
The paper is honest about what has not been solved. Rural availability lags, and with many manufacturers supplying generics there is scope for differences in quality and pharmacokinetics between branded generics — a real consideration when a patient's control changes after a pharmacy substitution rather than a prescription change.
The framing for readers elsewhere is that this is a policy result, not a market accident: coordinated pricing regulation, regulatory efficiency and domestic manufacturing capacity produced it.
- Check the current price of an SGLT2 inhibitor or GLP-1 receptor agonist before concluding a patient cannot afford one
- Ask which brand of generic a patient is actually dispensed, and note it — substitution can precede an unexplained change in control
- Confirm whether the patient is covered under Ayushman Bharat before assuming out-of-pocket cost
- In rural practice, check supply as well as price; the two have not fallen together
- Record cost as the reason where a drug is not started, so the decision can be revisited when prices move
The statistics, in plain English
The 15- to 65-fold cross-national differences compare Indian generic prices with US list prices, which is not what an insured American patient pays, so the ratio overstates the gap in real out-of-pocket terms. The 60-90% reduction is a fall from the pre-expiry originator price, not a statement that the drug is now affordable for any given patient; for a daily medicine taken for life, what matters is the monthly cost against household income, which this analysis does not report per patient.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free